Tarsus joins Stargardt race to market with $800m Alkeus takeover
Tarsus Pharmaceuticals has forged a takeover deal with Alkeus Pharmaceuticals worth up to $800m, adding a Stargardt disease asset with…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Context drops bispecific T-cell engager on cost-cutting initiative
Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the…
-
Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead
The US Food and Drug Administration (FDA) has approved Takeda’s oral orexin receptor agonist, oveporexton, for a form of narcolepsy…
-
Mironid banks $46m in Series B to take rare kidney disease drug closer to clinic
Scottish biopharmaceutical company Mironid has pocketed $46m in Series B funding raise to progress the development of its lead rare…
-
Supernus and Indivior merge to create scaled, CNS-focused entity
Supernus Pharmaceuticals and Indivior Pharmaceuticals are joining forces to create a diversified and scaled biopharmaceutical company focused on the central…
-
Amgen contends with data breach, exposing patient information
Amgen has been hit with a data breach impacting its third-party operated cloud-based systems – an event which the company…
-
Boosting CGT access: a global consideration with wide-spanning benefits
Back in 2014, Jonathan Clark’s world was flipped on its head when he was diagnosed with mantle cell lymphoma (MCL)…
-
J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout
Johnson & Johnson (J&J) is venturing further into the increasingly crowded in vivo CAR-T market, this time through an autoimmune…
-
EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals
European drug regulators have been busy this week – opting to approve several medicines from companies like AbbVie, Pfizer &…
-
The $1.2tn untapped pharma opportunity in tropical conservation
The tropical rainforests situated across the global South could represent a lucrative, trillion-dollar opportunity for pharma, as concerns around deforestation…